Riding the Wegovy wave: The startups shifting focus to GLP-1s to tap the $150bn weight loss drug market
The meteoric rise of a new class of weight loss drugs over the past two years, known as GLP-1s, has seen a new name take the title of Europe’s most valuable company, helped a country dodge a recession and hit grocery sales in the US. The valuations of the …